Affinity Asset Advisors
NTLA icon

Affinity Asset Advisors’s Intellia Therapeutics NTLA Stock Holding History

Affinity Asset Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.22M Buy
+350,000
New +$4.38M 0.17% 83
2022
Q1 		– Sell
-10,000
Closed -$1.18M – 69
2021
Q4 		$1.18M Sell
10,000
-5,000
-33% -$626K 0.43% 44
2021
Q3 		$2.01M Buy
15,000
+5,000
+50% +$757K 0.51% 40
2021
Q2 		$1.62M Buy
+10,000
New +$779K 0.58% 40

Other funds holding NTLA

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $17.4B AUM 41.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Tarrytown, New York $180M AUM 18.92% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $8.04B AUM 33.34% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Affinity Asset Advisors's NTLA Position: Q3 2026 in Review

Affinity Asset Advisors opened a new position in Intellia Therapeutics (NTLA) in Q3 2026: 350,000 shares worth $4.22M. The stake represents 0.17% of the portfolio and ranks #83 among its holdings. This is a return to the name: Affinity Asset Advisors previously reported a position in NTLA as recently as Q4 2021.

Affinity Asset Advisors first reported a position in NTLA in Q2 2021 and has held it in 4 quarters since. 239 funds tracked by Wall St. Rank hold NTLA as of Q3 2026.

  • Affinity Asset Advisors held 350,000 shares of Intellia Therapeutics worth $4.22M as of Q3 2026.
  • Intellia Therapeutics was a new Affinity Asset Advisors position in Q3 2026.
  • Intellia Therapeutics made up 0.17% of Affinity Asset Advisors's portfolio in Q3 2026, its #83 holding.
  • Affinity Asset Advisors first reported a position in Intellia Therapeutics in Q2 2021 and has held it in 4 quarters since.
  • 239 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2026.

Based on Affinity Asset Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.